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1. Purpose
Diabetes  (DM) is the world’s fastest-growing disease being responsible for almost 3mellitus
 million deaths per year [1]. In the recent years, vanadium compounds have attracted a lot of
interest due to their potential therapeutic application, particularly in the treatment of DM [2].
Many V(IV) and V(V) complexes have been synthesized to improve specific properties such as
hydrolytic stability, water solubility, neutral charge and/or lipophilicity, and their toxicity and
insulin mimetic action have been evaluated.
 In this work we report an  studyin vivo with a pre-diabetic animal model - Zucker fatty (fa/fa)
 rats - treated during four weeks with the compound VO(dmpp) (Fig. 1) [3]2 .
This vanadium compound has previously shown promising insulin-mimetic properties through 
 studies in rat adipocytes [4]. In this work, the gain of body weight was daily determinedex vivo
and a glucose tolerance test was performed at the end of the study. Hepatic and subcutaneous
lipid content were assessed by Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS). The
 obtained results show that gain of body weight (Fig. 2), hepatic triglycerides content (Fig. 3)
  and subcutaneous fat width (Fig. 4) were significantly lower in obese-treated Zucker rats than in
obese non-treated Zucker rats. In addition, the typical glucose intolerance profile of fatty rats
 was reversed by the action of VO(dmpp)  (2 Fig. 5).
 All these results corroborate with previous ex vivo data [4], showing that VO(dmpp)  is able to2
restore normal glucose and lipid metabolism in Zucker fatty rats, by effectively reverting some
of their pathological pre-diabetic indexes.
Molecular structure of VO(dmpp)2
Figure 1- Schematic representation of the molecular structure of the V(IV) complex V O(dmpp)IV
  -2 bis-[3-hydroxy-1,2-dimethyl-4-pyridinonate] oxovanadium (IV).
2. Material and Methods
 studies were conducted using 7 weeks-old Zucker lean (fa/+) (controls) and Zucker fattyIn vivo
(fa/fa) rats (a pre-diabetic animal model characterized by normoglycaemia, hyperinsulinaemia,
hyperlipoproteinaemia, hyperphagia, hepatic and peripheral insulin resistance and obesity [3]).
   The animals were divided in four different groups: VO(dmpp) -treated2 lean (n=8), non-treated
    lean(n=8), VO(dmpp) -treated2 obese (n=8) and non-treated obese (n=8).
During four weeks, the lean-treated and obese-treated animals were daily intraperitoneally
  (i.p.) injected with a solution containing the V(IV) species resulting from the dissolution of VIV
O(dmpp)  in physiological serum under aerobic conditions (15mg/Kg body weight). Lean and2
obese non-treated animals were injected with the same volume of physiological serum.
Once a week (on days 1, 8, 15, 23 and 30), the animals were assessed in terms of hepatic
triglyceride (HTG) content determined by H MRS.  MRI and H MRS studies were1 In vivo 1
performed on a 7 T Bruker Pharmascan using a 60mm inner diameter volume coil for
radiofrequency transmitting and signal receiving.
On day 31, a glucose tolerance test was performed. After an i.p. injection of glucose (glucose
load: 1.5mg/g body weight), at the minute 0, blood glycemia was assessed during the following
120 minutes, in pre-determined intervals (0, 15, 30, 60 and 120 minutes).
3. Results
1. Gain of rat body weight
 Figure 2 – Graphical representation of gain of body weight of lean and obese Zucker rats during
  VO(dmpp) -treated lean rats (grey losanges, n=8), non-treated lean ratsVIVO(dmpp)2 treatment: 2
(grey squares, n=8), VO(dmpp) -treated obese rats (green triangles, n=8) and non-treated obese rats2
(black circles, n=8). Gain of body weight was calculated by normalizing daily weight values according
to weight values at Day 0. Data are shown as mean values ± SEM. Paired bilateral  test was used int
statistical analysis where  < 0.05 was considered to be significant. *  < 0.05; treated-obese P P vs.
non-treated obese at Day 30.
2. Assessment of Hepatic Triglycerides Content by MRI / MRS
 Once aFigure 3 – Assessment and quantification of Hepatic Triglycerides Content (%) by MRS.
week, during four weeks, the HTG content was measured in each group of animals.  Representative (A)
H MRS spectra acquired in the liver, along the different weeks of the treatment, are shown for1
VO(dmpp) -treated fatty Zucker rats and non-treated fatty Zucker rats. PRESS sequence was used to2
acquire the spectra in all cases. Water signal appears at 4.7 ppm whereas fat signal constituted by
methylene (CH )  and methyl (CH ) groups is observed between 1.2-1.5 ppm.  HTG content was2 n 3 (B)
quantified by H MRS. H MR spectra were acquired from four different ROIs (Region Of Interest) in the1 1
liver of each animal. The intensity of the water and fat signals was used to calculate the HTG
percentage in arbitrary units through the formula: [ H ((CH )  + CH ) ] / [ H (H O) 1 2 n 3 peak area
1
2 peak area
] x 100. This procedure was performed during four weeks, for VO(dmpp) -treated lean rats (n=8),2
non-treated lean rats (n=8), VO(dmpp) -treated obese rats (n=8) and non-treated obese Zucker rats2
(n=8). The increase in liver fat content is reflected as an increase in the intensity of the fat H MRS1
signal and thus an increase in the value of HTG percentage. Data are shown as mean values ± SEM.
Paired bilateral  test and one-way ANOVA were used in statistical analysis to compare two or moret
groups respectively, where  < 0.05 was considered to be significant.   < 0.005; Obese-treated ratsP ** P
in Day 0 . Day 8 . Day 15 . Day 23 . Day 30.   < 0.0005; Obese-treated  Obese non-treatedvs vs vs vs *** P vs.
at Day 30.
3. Subcutaneous adipose tissue thickness as detected by MRI
Figure 4 – Coronal T1W images of the liver of four different rats acquired with MSME sequence:
non-treated lean Zucker rat , VO(dmpp) -treated lean Zucker rat , VO(dmpp) -treated obese(A) 2 (B) 2
Zucker  non-treated obese Zucker rat , in the 1  (top) and in the 30  day of the study (bottom).(C) (D) st th
The difference between the subcutaneous fat width of obese-treated and obese non-treated rat is
shown by the arrows.
4. Glucose Tolerance Test
 The glucose measurements (g/100mL) were performed atFigure 5 – Glucose Tolerance Test.
different time points in the four groups of animals: VO(dmpp) -treated lean (n=8), non-treated lean2
(n=8), VO(dmpp) -treated obese (n=8) and non-treated obese (n=8) Zucker rats. Glucose load was2
injected at 0 min. Data are shown as mean values ± SEM. Paired bilateral  test was used in statisticalt
analysis where  < 0.05 was considered to be significant. *  < 0.0005 relative to glucose concentrationP P
of obese non-treated Zucker rats at the minute -10.
4. Conclusion
After 4 weeks of V O(dmpp)  treatment, different parameters indicative of insulin resistance, obesityIV 2
and pre-diabetic state were reverted in fatty (fa/fa) Zucker rats, such as gain of body weight, HTG high
content, subcutaneous fat width and glucose intolerance profile.
This study demonstrates the  activity of V O(dmpp) . This compound restores glucose andin vivo IV 2
lipid metabolism in fatty Zucker rats, reverting their metabolic profile of insulin resistance and
pre-diabetic condition.
Current studies are being conducted to confirm the insulin-mimetic properties of this vanadium
compound, which seems to be a promising drug to be further tested in different animal models.
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